Physician profile
Fred J Mcdonnell
NPI 1891897260
$5,766.65
in general payments reported to CMS, 2019-2025
33 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,496 · 2020: $1,164 · 2021: $986 · 2022: $774 · 2023: $556 · 2024: $520 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,347.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $865.63 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $761.43 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $699.62 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novartis Pharmaceuticals Corporation | $517.24 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $302.62 | 2019-2022 | |
| Glaxosmithkline, LLC. | $279.25 | 2020-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $256.23 | 2019-2025 | Mounjaro, Zepbound |
| Mylan Specialty L.P. | $244.49 | 2022-2024 | Yupelri |
| Amgen INC. | $242.65 | 2019-2020 | |
| Abbvie INC. | $241.13 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $194.95 | 2019-2024 | Verquvo, Capvaxive, Gardasil 9 |
| Abbott Laboratories | $136.71 | 2019-2024 | Freestyle Libre |
| Vanda Pharmaceuticals INC. | $115.54 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.23 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $109.01 | 2019-2023 | Eliquis |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.86 | 2019-2023 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $76.85 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $57.68 | 2024-2025 | Gemtesa |
| Allergan, INC. | $57.44 | 2019-2020 | |
| Lundbeck LLC | $53.77 | 2024 | Rexulti |
| Avanir Pharmaceuticals, INC. | $42.84 | 2021-2022 | |
| Global Blood Therapeutics, INC. | $34.48 | 2020 | |
| Philips North America LLC | $30.87 | 2021 | |
| Bioventus LLC | $30.41 | 2019 | |
| Redhill Biopharma INC. | $30.36 | 2020 | |
| Astellas Pharma US INC | $29.49 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $28.80 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $26.91 | 2022 | |
| Axsome Therapeutics, INC. | $22.26 | 2023 | Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.50 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $13.97 | 2022 | |
| Genentech USA, INC. | $13.89 | 2021 | |
| Boston Scientific Corporation | $13.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Mcdonnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.